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Abstract  
BACKGROUND: Probiotics are becoming increasingly popular treatment for children diarrhea. 
Although there are several probiotic strains potentially useful, researches were often limited to 
certain strains.  
AIM: To test Bifidobacterium lactis on morbidity of acute diarrhea in children less than 2 years.  
SUBJECTS AND METHODS: A randomized double-blind controlled clinical trial was conducted in 
50 children (1 - 23 months) admitted with acute diarrhea to the Pediatric Hospital, Cairo University 
and were randomly assigned to receive in addition to usual treatment of diarrhea according to WHO 
guidelines; one of two treatments either milk formula non-supplemented (n = 25) or supplemented 
(n = 25) with Bifidobacterium lactis 14.5 x 10
6
 CFU/100 ml daily for one week. Primary outcomes 
were frequency and duration of diarrhea and hospital stay. Secondary outcomes were duration of 
fever and vomiting episodes. Safety and tolerance were also recorded.  
RESULTS: On admission, patients’ characteristics of both groups (50 cases) were similar. For 
children who received the probiotics for one week; mean duration of diarrhoea was shorter than in 
controls (3.12 ± 0.92 vs. 4.10 ± 0.94 days) (P = 0.02), number of motions per day was less than in 
controls (3.96 ± 0.62 vs. 4.46 ± 0.85) (P = 0.04) and discharge from hospital <2 days was more 
frequent than in controls (72% vs. 44%) (P = 0.048). There was no effect on fever (P = 0.63) or 
vomiting (P = 0.54).  
CONCLUSION: Bifidobacterium lactis probiotics in supplemented milk formula decreased 
significantly frequency, duration of diarrhea, and hospital stay than usual treatment alone in children 
with acute diarrhea. Additional researches on other uncommon local probiotic species should be 
encouraged. 
 
 
 
 
Introduction 
 
The use of probiotics, discussed primarily in 
the context of alternative medicine and now entering 
mainstream medicine, only a few have been 
confirmed in well-designed controlled trials [1].  
Probiotics according to FAO/WHO [2] are live 
microorganisms which when administered in adequate 
amounts confer a health benefit on the host. Research 
studies on probiotics vary according to type of genera, 
species and strain used beside additional intervention 
characteristics such as the dose, potency, treatment 
duration, viability of the organism, as well as the 
combination of strains [3]. Of the probiotics derived 
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from food sources (cultured milk products); lactic acid 
bacteria (e.g., Lactobacillus and Bifidobacterium), 
Saccharomyces boulardii (a non-pathogenic strain of 
yeast), Enterococcus faecium, Streptococcus 
thermophiles, Pediococcus acidilactici, Bacillus 
coagulans and a non-pathogenic strain of Escherichia 
coli (e.g., E. coli Nissle, 1917). In children, probiotics 
were recommended to be used in allergies, 
inflammatory bowel disease, irritable bowel syndrome 
and necrotizing enterocolitis [4]. They are commonly 
used in treatment and prevention of acute diarrhea [5, 
6]. Application of probiotics in treating acute children 
diarrhoea has increasingly become a subject of 
research interest. It has been reported that probiotics 
decrease the duration of diarrhoea and fever 
significantly in children [7].  
The strongest evidence of a beneficial effect 
of probiotics has been established with L. rhamnosus 
GG [8] and B. lactis BB-12 [9] for prevention and 
Lactobacillus reuteri SD2222 for treatment of acute 
rotavirus diarrhea in children [10]. Common strains 
used to treat diarrhea include: L. rhamnosus [11], L. 
acidophilus [12], L. casei [13], L. reuteri [14], B. 
bifidum [15], B. longum [16], S. boulardi [17], E. 
faecium [18]. Probiotics for diarrhea exert their action 
possibly through direct or indirect mechanisms 
including immune modulation, inhibition of pathogenic 
bacteria, enhancing barrier function and production of 
antimicrobial agents [19].  
Bifidobacteria are particularly attractive as 
probiotics agent because they constitute the 
predominant colonic flora of breastfed infants and are 
thought to play a role in the decreased incidence of 
diarrhea in breastfed infants [20]. 
However, there are few studies investigating 
the role of this probiotics. In this study we investigated 
the effect of using 14.5 x 10
6
 CFU/100 ml daily of 
Bifidobacterium lactis in supplemented milk formula 
for children acute diarrhea.  
 
 
Subjects and Methods  
 
The study protocol was approved by the 
ethical committee of the National Research Center 
and Pediatric Department of Cairo University. 
Informed written consent was obtained from parents 
of children enrolled in the study. 
Fifty children 1 to 23 months of age with acute 
diarrhea due to gastroenteritis were enrolled in this 
prospective, double blind, randomized study 
conducted on admitted children with acute diarrhea to 
the Paediatric Hospital, Cairo University between July 
and September 2014. Diarrhoea was defined as 
passage of three or more loose stools in the last 24 
hours [21]. 
Children with severe malnutrition (weight for 
height < 3 SD of WHO charts), dysentery (presence of 
visible blood in stools), clinical evidence of co-existing 
acute systemic illnesses (e.g. meningitis, sepsis, 
pneumonia) and clinical evidence of chronic disease 
(e.g. chronic gastrointestinal disease, chronic liver 
disease, and chronic renal disease) were excluded 
from the study. Subjects in whom probiotics were 
used in the preceding four weeks or if antibiotics were 
used for current episode of diarrhoea, were also 
excluded from the study.  
Each patient’s demographic data, medical 
history, feeding pattern and stooling characteristics 
were recorded. Feeding parameters included number 
of meals per day, response to food (on a 1–5 scale), 
daily formula volume, and daily number of 
regurgitation, degree of dehydration, and the 
symptoms associated with gastroenteritis (duration of 
diarrhea, number of motions, fever, vomiting), duration 
of hospital stay, growth parameters, safety and 
tolerance were also recorded. Clinical assessment of 
dehydration was done according to clinical 
dehydration scale [22].  
Patients with severe dehydration had been 
excluded from the study. The patients estimated as 
moderate dehydration with no oral tolerance had 
needed to be hospitalized. From each patient with 
diarrhea a stool sample was analyzed for routine 
bacterial cultures (including Salmonella, Shigella, 
Campylobacter, and Yersinia species, excluding 
toxigenic Escherichia coli), rotavirus, ova and 
parasites, including Cryptosporidium. 
 
Randomization 
All included children were randomized to 
receive either milk formula with Bifidobacterium Lactis 
(B. lactis group) or no probiotics milk formula (control 
group) using serially numbered sealed opaque 
envelopes. 
 
Intervention 
All the studied patients with acute diarrhea 
received the usual treatment according to WHO 
guidelines [20]; in addition the B. lactis group received 
formula with Bifidobacterium Lactis using 14.5 x 10
6
 
CFU (colony forming unit)/100 ml daily for 7 days and 
the control group received milk formula with no 
Bifidobacterium Lactis for 7 days. During the study 
period, patients were followed up in the hospital; to 
elicit frequency of diarrhea, episodes of vomiting or 
fever per day and the total duration of diarrhea.  
 
Statistical analysis 
Data was grouped as patients and control and 
analyzed using SPSS for windows version 16.0 
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(SPSS Chicago, IL.). Parametric (numeric) data were 
expressed as mean (SD) and compared using 
independent sample t-test. Non parametric data were 
expressed as frequency (number, percent) and 
compared using Mann- Whitney U test. Two tailed 
significant values were considered when p< 0.05. 
 
 
Results 
 
A total of 50 children below 2 years of age 
fulfilled the protocol inclusion and exclusion criteria; 
were enrolled in this study. The initial demographic 
and clinical data of the two groups studied; 25 patients 
receiving milk formula with Bifidobacterium Lactis (B. 
lactis group) and 25 receiving milk formula with no 
Bifidobacterium Lactis (control group) were illustrated 
in Table 1.  
Table 1: Study population baseline characteristics 
 
B. lactis group 
(n = 25) 
Control group 
(n = 25) 
P value 
Age ,months *  12.36 ( 6.07) 11.84 (6.56) 0.77 
Gender * *  
Male  
Female 
15 (60) 
10 (40) 
16 (64) 
9 (36) 
0.77 
Body weight, kg * 9.52 (2.67) 8.51 (2.10) 0.15 
 
Duration of diarrhea before 
randomization, hours * 
 
48.31 (9.44)  
 
51.03 (8.16) 
 
0.76 
Children with fever * * 7 (28) 6 (24) 0.63 
Children with vomiting * * 5 (20) 6 (24) 0.64 
* mean( SD); * * number (%). 
 
There were no significant differences (P > 
0.05) between the two groups at randomization in 
terms of age at entry, birth weight, gender, 
breastfeeding before the study. The mean daily 
formula volume did not differ significantly between the 
control and B. lactis group (means [SD]: 589.4 [76.0] 
vs 578 [69.7] mL, respectively; P = 0 .288). 
Furthermore, no significant differences were observed 
between groups in terms of other feeding 
characteristics (daily number of meals, regurgitation 
and vomiting episodes). 
The mean duration (hours) of diarrhea before 
treatment was 48.31 ± 9.44 in (B. lactis group) and 
51.03 ± 8.16 in (control group) (P = 0.76). Percentage 
of fever in B. lactis group was 28% and 24% in control 
group (P = 0.63). Percentage of vomiting in B. lactis 
group was 20% and 24% in control group (P = 0.64). 
After 7 days of treatment the primary 
(frequency and duration of diarrhea, hospital stay) and 
secondary outcomes (frequency of vomiting and 
duration of fever) as illustrated in Table 2, indicated 
that the mean duration of diarrhea (days) after 
treatment was significantly shorter in children 
receiving B. lactis (P = 0.03).  
Frequency of diarrhea (number of motions per 
day) after treatment was significantly lower in children 
receiving B. lactis (P = 0.04). The duration of hospital 
stay was significantly less in children receiving B. 
lactis ; 32% of children receiving B. lactis discharged 
form hospital before 2 days compared to 44% of 
control group (P = 0.04). There was no significant 
difference regarding reduction in episodes of fever 
and duration of vomiting in both groups. No adverse 
effects were noted in both groups. 
Table 2: Primary and secondary outcome measures 
 
B. lactis group 
(n = 25) 
Control group 
(n = 25) 
 
P value 
Duration of diarrhea after 
randomization, (days) *  
3.12 ± 0.92 4.10 ± 0.94 0.02 
Episodes of diarrhea /day *  3.96 (0.62) 4.46 (0.85) 0.04 
Duration of hospital stay * * 
 < 2 days 
 > 2 days 
 
18 (32) 
 7 (28) 
 
11 (44) 
14 (56) 
0.04 
Episodes of vomiting / day * 3.21 (0.33) 3.55( 0.06) 0.34 
Duration of fever ,days * 2.27 (0.85) 2.79 (0.64) 0.56 
* mean ( SD); * * number (%). 
 
   
 
 
Discussion 
 
This randomized double-blind controlled 
clinical trial demonstrated that for children under two 
years of age suffering from acute diarrhea, 
administration of 14.5 x10
6
 CFU/100 ml daily of 
Bifidobacterium Lactis in a supplemented milk formula 
for 7 days results in less frequent episodes with 
shortening of the duration of diarrhea and less 
duration of hospital stay.  
Probiotics have been most extensively 
studied in the treatment of diarrheal diseases, where 
their efficacy can be considered well established. Only 
a limited number of probiotic strains have been tested, 
and, as the effects of different probiotic 
microorganisms are not equivalent, results cannot be 
generalized [1]. 
There are many microorganisms that could 
potentially function as probiotics, of which 
Lactobacillus and Bifidobacterium species are the 
most commonly used. The genus Bifidobacterium 
includes various Gram positive non-motile anaerobic 
bacteria. They are endosymbiotic inhabitants of the 
gastrointestinal tract and vagina of mammals, 
including humans [23]. 
Strains of the genus Bifidobacterium are also 
often used as probiotic bacteria as they are known for 
their variety of resistance mechanisms to bile salts, 
which is important since the beneficial effects of 
probiotic bacteria must be generated in the presence 
of this biological fluid. It has even been proven that 
although bile tolerance is strain dependent, wild type-
bile sensitive bifidobacteria strains can progressively 
adapt to the presence of bile salts by subculturing and 
gradually increasing concentration of bile [24].  
In addition, non-pathogenic species belonging 
to the class of Saccharomyces, Streptococcus and 
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Lactococcus are also used as probiotics [25]. 
Pathogens are microorganisms that may cause 
disease in their host. The ability to inhibit pathogens is 
one of the three main mechanisms of probiotics, 
barrier function enhancement and immune 
interactions being the other two. It is proposed that 
pathogen inhibition is facilitated through multiple 
mechanisms including: production of inhibitory 
substances (organic acids, H2O2, bacteriocins); 
nutrient competition; toxin removal/degradation; 
competition for sites of adherence (mucus, cell 
receptors); co-aggregation and virulence modulation; 
and induction of host immune responses by inducing 
immune-modulatory activity, including recruitment of 
CD4 + T-helper cells [26]. 
Of the studies on probiotics effect in children 
diarrhea; a Cochrane review [27] found that the use of 
LGG reduced the duration of diarrhea and mean stool 
frequency on day 2, while in a more recent systematic 
review [28] LGG had no effect on the total stool 
volume but significantly reduced the duration of 
diarrhea compared with placebo or no treatment. LGG 
was more effective when used at a daily dose of >10
10 
colony-forming units (CFU). Another Cochrane review 
[29] documented that the use of S boulardii reduced 
the risk of diarrhea lasting >4 days. The use of S 
boulardii significantly reduced both the duration of 
diarrhea and the risk of diarrhea on day 3. Similar 
results were found using L reuteri DSM 17938 [30].  
Studies on B lactis are not frequent, one RCT 
[31] conducted on 224 Chinese children ages 6 to 36 
months evaluated the effect of a lactose-free formula 
supplemented with 2 doses of a mixture of B lactis 
B12 and S thermophilus TH4 compared with 
unsupplemented formula. Regardless of the dose 
used, the duration of diarrhea was the same in both 
groups. In our study we used B lactis in a daily dose 
of 14.5 million CUF/100 ml and this dose was 
sufficient to induce reduction in frequency and 
duration of diarrhea.  
In the present study, based on the average 
daily intake of formula, the mean daily ingested dose 
of Bifidobacterium Lactis was 14.6 x10
8
 CFU/day, and 
according to a recent study, oral administration of 
lactobacilli at levels ranging from 10
8
 to 10
10
 CFU/day 
has led to transient colonization of the infant 
gastrointestinal tract [32]. Most of the stool pathogens 
in our series were probably viral. Stool analysis for 
rotavirus was positive in 66%, none of stool samples 
were positive for routine bacterial cultures. This 
finding is in accordance with many previous studies 
demonstrating that probiotic agents are able to treat 
intestinal infections, mainly of viral etiology [33, 34]. 
The mechanisms by which probiotic agents 
might exert their therapeutic effect against viral 
pathogens in particular are mostly unknown. An 
increased humoral response, including an increase in 
IgA-specific antibody-secreting cells against rotavirus, 
was described in children with acute rota viral diarrhea 
who received Lactobacillus GG [35]. Another study 
[36] showed that dietary treatment using B. lactis 
HN019 can reduce the severity of weanling diarrhea 
associated with rotavirus and E. coli, possibly via a 
mechanism of enhanced immune-mediated 
protection. That study suggested that probiotic 
treatment may be an effective dietary means of 
preventing or limiting diarrhea in human infants.  
Bifidobacterium lactis was tested for 
prevention of diarrhea in a randomized control trial 
[37] of a commercial probiotic containing 
Bifidobacterium lactis and S. thermophilus involved 
157 infants, 6 to 36 months of age. That study found a 
significant difference in the incidence of antibiotic-
associated diarrhea in children receiving probiotic-
supplemented formula (16%) compared with non-
supplemented children. Our study was applied for 
children with acute viral diarrhea with exclusion of 
antibiotic associated causes.  
As regarding safety, no adverse effects were 
noted in our study. Bifidobacteria are generally 
regarded as nonpathogenic, because they occur 
naturally in the intestine. In many clinical trials these 
agents seem to be safe for the general pediatric 
populations and in particular in infancy [38].  
Depending on the presence of great variety of 
species and strain characteristics of probiotics, there 
is always a need for more controlled clinical studies 
investigating new types of probiotics. 
We concluded that Bifidobacterium lactis 
probiotics in supplemented milk formula decreased 
significantly frequency, duration of diarrhea, and 
hospital stay than usual treatment alone in children 
with acute diarrhea. Additional researches on other 
uncommon local probiotic species should be 
encouraged.  
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